Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index; none of the 8 sources its claims cite is checked for support yet.

The evolving clinical picture of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A look at 1310 patients over 16 years

Open access
Doiron, R. Christopher, Tripp, Dean A., Tolls, Victoria, Nickel, J. Curtis · 2018 · Canadian Urological Association Journal

Abstract

Introduction: Two decades of increasing understanding of etiopathogenesis and clinical phenotyping produces an impression the clinical face of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is changing. We sought to retrospectively analyze trends in CP/CPPS patients presenting to our clinic for evaluation over a 16-year period.Methods: Patients with CP/CPPS presenting to a tertiary clinic were evaluated prospectively from 1998–2014 with Chronic Prostatitis Symptom Index (CPSI) and UPOINT (urinary, psychosocial, organspecific, infection, neurogenic, and tenderness) categorization. Patients were stratified in four cohorts, based on year of presentation, and we retrospectively analyzed variations in symptom scores and patterns, UPOINT categorization, and treatment modalities amongst cohorts.Results: Mean age of the 1310 CP/CPPS patients was 44.7 years, while mean CPSI pain, urination, and total scores were 10.6, 4.8, and 23.3, respectively. The most prevalent UPOINT domain, urinary (U) (71.8%) was associated with a higher CPSI urination score (6.3), more frequent penile tip pain (37%), dysuria (48%), and more treatment with alpha-blockers (70%). Increase in UPOINT domains was associated with higher CPSI pain, quality of life (QoL), and total scores. Trends over time included increased prevalence of psychosocial (P), organ (O), and tenderness (T) domains, as well as increased use of alpha-blockers, neuromodulation, and phytotherapy as treatment modalities. There was little variation in age, CPSI scores, and pain locations over time.Conclusions: The changing clinical face of CP/CPPS reflects the increased recognition of psychosocial (P domain) and pelvic floor pain (T domain), along with the concomitant use of associated therapies. There was little variation of pain/urinary symptom patterns and QoL.

Overview

CoChat Summary

TL;DR

In a single tertiary clinic, 1310 Category III CP/CPPS patients evaluated from 1998–2014 showed stable age, CPSI symptom scores, and pain locations over time, while UPOINT phenotypes shifted toward more psychosocial, organ-specific, and tenderness domains and less infection domain. Referring-physician treatments increased for alpha-blockers, neuromodulation, and phytotherapy, with antibiotics used in 22.4% overall and no significant trend.

Key findings

  • Overall cohort mean age was 44.7 years; mean CPSI pain, urination, QoL, and total scores were 10.6, 4.8, 7.9, and 23.3. Most prevalent UPOINT domain was urinary (U) at 71.8%, followed by organ-specific (O) 50.4%, tenderness (T) 49.2%, infection (I) 33.6%, neurologic (N) 30.7%, and psychosocial (P) 27.6%.
  • Increased UPOINT domains were associated with higher CPSI pain (14.3), worse QoL (10.9), and higher total CPSI (31.4). The U domain was associated with higher CPSI urination (6.3), more penile tip pain (37%), more dysuria (48.2%), and more alpha-blocker treatment (70%); the P domain was associated with higher UPOINT total (3.3), antidepressants (29.1%), and gabapentinoids (10.2%).
  • Over time, prevalence increased for P (p=0.0009), O (p<0.0001), and T (p<0.0001), and decreased for I (p<0.0001). Treatment increased for alpha-blockers (p<0.0001), neuromodulation (p<0.0001), and phytotherapy (p=0.0001); antibiotics ranged from 20.5%–27.2% across cohorts with no significant change (p=0.1759).
  • There was little variation in age, CPSI scores, and pain locations over time; pain location was not associated with disease severity, UPOINT domain, or treatment modality.

Methods

  • Retrospective analysis of a prospective clinical quality assurance database: 1349 CP patients evaluated 1998–2014 at a single tertiary outpatient clinic by a single urologist; 39 Category II bacterial prostatitis patients were excluded, leaving 1310 Category III CP/CPPS patients.
  • Data collected at initial presentation included demographics, symptom duration, CPSI (pain, urinary, QoL/impact), and UPOINT; UPOINT scoring was retrospective before 2009 and prospective from 2009, and treatments recorded were those provided by referring physicians prior to or at evaluation.
  • Patients were stratified into four cohorts by presentation year (1998–2001, 2002–2005, 2006–2009, 2010–2014). Continuous variables (age, CPSI) were analyzed by ANOVA; categorical variables (UPOINT, pain locations, treatments) by Chi-squared Test for Trend in Proportions; p<0.05 was significant.

Limitations

  • Stated in the paper: the study is retrospective, from a single outpatient clinic, with evaluations by a single urologist; UPOINT scoring was retrospective before 2009 and prospective from 2009; treatment data reflect referring-physician interventions before/at initial evaluation; the authors note it is difficult to know whether phenotype-directed treatment made a significant difference to patient outcome.
  • Evident from the design: no control/comparison group and no post-treatment outcome data are reported in this analysis; the authors also suggest that increased P and T domain prevalence likely reflects referring physicians’ recognition rather than a change in the patient population.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.5489/cuaj.4876

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 6 Not checked · 45 Own results and interpretations

34 more claims

Create a free account to see all 51 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 5

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. Nickel JC. Prostatitis. Can Urol Assoc J 2011; 5: 306-15.

Cited by

See all 24

Metadata

Authors
Doiron, R. C., Tripp, D. A., Tolls, V., & Nickel, J. C.
Affiliations
Queen's University (CA)
Venue
Canadian Urological Association Journal
Published
2018-02-19
Volume
12
Issue
6
Pages
196-202
ISSN
  • 1911-6470 (ISSN-L)
  • 1920-1214
OpenAlex
W2791876036
Cited by
24
References
17
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2022: 5 · 2021: 4 · 2020: 2 · 2019: 8 · 2018: 1
FWCI
3.92
Type
journal article
Language
en
Open access
Locations
  • Canadian Urological Association Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Funders
  • National Institutes of Health
  • Canadian Institutes of Health Research
  • National Institute of Diabetes and Digestive and Kidney Diseases
Topics
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
Keywords
chronic prostatitis/chronic pelvic pain syndrome, clinical phenotyping, Chronic Prostatitis Symptom Index, psychosocial symptoms, urinary symptoms, dysuria, alpha-blockers, neuromodulation, herbal medicine, quality of life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.